Clinical significance of secondary cytoreductive surgery for recurrent advanced ovarian cancer.
- Author:
Rongyu ZANG
1
;
Zhiyi ZHANG
;
Shumo CAI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Female; Humans; Logistic Models; Middle Aged; Neoplasm Recurrence, Local; surgery; Neoplasm, Residual; surgery; Ovarian Neoplasms; surgery; Prognosis; Survival Analysis
- From: Chinese Journal of Oncology 2002;24(2):194-196
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the role of secondary cytoreductive surgery (SCR) in patients with recurrent advanced epithelial ovarian cancer.
METHODSFrom Jan. 1986 to Dec. 1997, 60 women with recurrent advanced epithelial ovarian cancer treated with SCR were retrospectively reviewed. Survival curves were computed using the Kaplan-Meier method with differences in survival estimated by log-rank test. Independent prognostic factors were identified by Cox's stepwise regression, and the affecting factors of SCR evaluated by Logistic stepwise regression.
RESULTSOf the 60 patients, 23 (38.3%) were cytoreduced to small macroscopic residual (
CONCLUSIONSecondary cytoreductive surgery is definitely effective in the treatment of recurrent advanced epithelial ovarian carcinoma, particularly in those who have received primary optimal cytoreduction with a progression-free interval > 12 months and without refractory ascites.
